| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 48.26M | 26.35M | 25.19M | 20.65M | 48.84M | 17.81M | 157.17M | 270.83M | 331.41M | 450.71M |
| Revenue Growth % | 2.55% | -0.45% | -0.04% | -0.18% | 1.36% | -0.64% | 7.82% | 0.72% | 0.22% | 0.36% |
| Cost of Goods Sold | 1.9M | 2.7M | 1.7M | 471K | 4.1M | 1.68M | 7.26M | 6.59M | 4.66M | 12.48M |
| COGS % of Revenue | 0.04% | 0.1% | 0.07% | 0.02% | 0.08% | 0.09% | 0.05% | 0.02% | 0.01% | 0.03% |
| Gross Profit | 46.36M | 23.65M | 23.48M | 20.18M | 44.73M | 16.14M | 149.91M | 264.23M | 326.75M | 438.23M |
| Gross Margin % | 0.96% | 0.9% | 0.93% | 0.98% | 0.92% | 0.91% | 0.95% | 0.98% | 0.99% | 0.97% |
| Gross Profit Growth % | 2.44% | -0.49% | -0.01% | -0.14% | 1.22% | -0.64% | 8.29% | 0.76% | 0.24% | 0.34% |
| Operating Expenses | 85.81M | 72.26M | 80.89M | 114.4M | 144.19M | 190.89M | 327.63M | 412.67M | 430.46M | 440.77M |
| OpEx % of Revenue | 1.78% | 2.74% | 3.21% | 5.54% | 2.95% | 10.72% | 2.08% | 1.52% | 1.3% | 0.98% |
| Selling, General & Admin | 13.05M | 11.25M | 13.93M | 29.51M | 37.12M | 67.93M | 118.82M | 159.37M | 213.89M | 266.13M |
| SG&A % of Revenue | 0.27% | 0.43% | 0.55% | 1.43% | 0.76% | 3.81% | 0.76% | 0.59% | 0.65% | 0.59% |
| Research & Development | 72.76M | 61.01M | 66.96M | 84.89M | 107.07M | 122.96M | 208.81M | 253.3M | 216.57M | 174.64M |
| R&D % of Revenue | 1.51% | 2.32% | 2.66% | 4.11% | 2.19% | 6.9% | 1.33% | 0.94% | 0.65% | 0.39% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -39.44M | -48.61M | -57.41M | -94.22M | -99.45M | -174.76M | -177.72M | -148.44M | -103.71M | -2.54M |
| Operating Margin % | -0.82% | -1.84% | -2.28% | -4.56% | -2.04% | -9.81% | -1.13% | -0.55% | -0.31% | -0.01% |
| Operating Income Growth % | 0.14% | -0.23% | -0.18% | -0.64% | -0.06% | -0.76% | -0.02% | 0.16% | 0.3% | 0.98% |
| EBITDA | -39.26M | -48.12M | -56.71M | -93.45M | -98.73M | -174.01M | -176.94M | -147M | -102.05M | -1.3M |
| EBITDA Margin % | -0.81% | -1.83% | -2.25% | -4.52% | -2.02% | -9.77% | -1.13% | -0.54% | -0.31% | -0% |
| EBITDA Growth % | 0.14% | -0.23% | -0.18% | -0.65% | -0.06% | -0.76% | -0.02% | 0.17% | 0.31% | 0.99% |
| D&A (Non-Cash Add-back) | 180K | 483K | 704K | 770K | 724K | 748K | 777K | 1.44M | 1.66M | 1.25M |
| EBIT | -37.82M | -48.66M | -57.22M | -92.08M | -97M | -168.31M | -122.52M | -145.29M | -117.99M | 11.56M |
| Net Interest Income | -4.67M | -5.69M | -7.55M | -6.92M | -9.96M | -5.08M | -59.23M | -93.97M | -92.46M | -83.77M |
| Interest Income | 535K | 793K | 1.01M | 2.25M | 1.93M | 9.42M | 62K | 5.13M | 15.78M | 14.75M |
| Interest Expense | 5.2M | 6.49M | 8.56M | 9.18M | 11.89M | 14.5M | 59.29M | 99.09M | 108.24M | 98.52M |
| Other Income/Expense | -3.58M | -6.54M | -8.37M | -7.03M | -9.44M | -8.06M | -4.09M | -95.95M | -122.52M | -84.41M |
| Pretax Income | -43.02M | -55.14M | -65.78M | -101.25M | -108.9M | -182.81M | -181.81M | -244.38M | -226.23M | -86.95M |
| Pretax Margin % | -0.89% | -2.09% | -2.61% | -4.9% | -2.23% | -10.26% | -1.16% | -0.9% | -0.68% | -0.19% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 2.25M | 2.73M | 310K | 1.93M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1.01% | 1.01% | 1% | 1.02% |
| Net Income | -43.02M | -55.14M | -65.78M | -101.25M | -108.9M | -182.81M | -184.06M | -247.12M | -226.54M | -88.88M |
| Net Margin % | -0.89% | -2.09% | -2.61% | -4.9% | -2.23% | -10.26% | -1.17% | -0.91% | -0.68% | -0.2% |
| Net Income Growth % | 0.05% | -0.28% | -0.19% | -0.54% | -0.08% | -0.68% | -0.01% | -0.34% | 0.08% | 0.61% |
| Net Income (Continuing) | -43.02M | -55.14M | -65.78M | -101.25M | -108.9M | -182.81M | -184.06M | -247.12M | -226.54M | -88.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.59 | -0.75 | -0.78 | -0.98 | -0.94 | -1.09 | -1.03 | -1.33 | -1.18 | -0.43 |
| EPS Growth % | 0.13% | -0.27% | -0.04% | -0.26% | 0.04% | -0.16% | 0.06% | -0.29% | 0.11% | 0.64% |
| EPS (Basic) | -0.59 | -0.75 | -0.78 | -0.98 | -0.94 | -1.09 | -1.03 | -1.33 | -1.18 | -0.43 |
| Diluted Shares Outstanding | 72.9M | 73.7M | 84.45M | 103.19M | 115.6M | 167.27M | 179.12M | 185.91M | 192.2M | 206.7M |
| Basic Shares Outstanding | 72.9M | 73.7M | 84.45M | 103.19M | 115.6M | 167.27M | 179.12M | 185.91M | 192.2M | 206.7M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 65.99M | 66.99M | 125.39M | 114.35M | 164.34M | 323.8M | 566.14M | 516.5M | 495.97M | 421.97M |
| Cash & Short-Term Investments | 99.25M | 63.58M | 155.69M | 126.84M | 136.23M | 300.37M | 507.6M | 424.31M | 388.99M | 321.06M |
| Cash Only | 28.9M | 22.1M | 50.28M | 26.73M | 114.17M | 272.13M | 504.39M | 304.77M | 110.64M | 104.92M |
| Short-Term Investments | 22.66M | 32.55M | 64.11M | 77.74M | 22.05M | 28.24M | 3.21M | 119.54M | 278.34M | 216.14M |
| Accounts Receivable | 6.24M | 8.77M | 6.12M | 4.29M | 22.15M | 8.65M | 29.41M | 50.6M | 56.95M | 79.07M |
| Days Sales Outstanding | 47.22 | 121.44 | 88.65 | 75.87 | 165.52 | 177.17 | 68.31 | 68.19 | 62.72 | 64.03 |
| Inventory | 1.61M | 500K | -37.8M | 1.65M | 0 | 7.04M | 15.79M | 27.53M | 28.68M | 8.09M |
| Days Inventory Outstanding | 310.33 | 67.62 | - | 1.28K | - | 1.53K | 793.46 | 1.52K | 2.25K | 236.42 |
| Other Current Assets | 1.7M | 1.63M | 3.5M | 1.54M | 1.55M | 2.22M | 3.35M | 14.06M | 21.35M | 13.75M |
| Total Non-Current Assets | 58.56M | 22.86M | 52.87M | 32.49M | 10.94M | 10.91M | 22.02M | 33.5M | 20.99M | 68.45M |
| Property, Plant & Equipment | 5.15M | 9.92M | 9.55M | 9.13M | 7.35M | 7.11M | 15.19M | 8.62M | 20.91M | 19.79M |
| Fixed Asset Turnover | 9.37x | 2.66x | 2.64x | 2.26x | 6.65x | 2.50x | 10.35x | 31.43x | 15.85x | 22.78x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 47.68M | 8.93M | 41.3M | 22.38M | 0 | 0 | 6.83M | 18.08M | 0 | 21.72M |
| Other Non-Current Assets | 5.73M | 4.01M | 2.03M | 978K | 3.59M | 3.8M | 0 | 6.81M | 80K | 26.94M |
| Total Assets | 124.56M | 89.85M | 178.26M | 146.84M | 175.28M | 334.71M | 588.15M | 550M | 516.96M | 490.42M |
| Asset Turnover | 0.39x | 0.29x | 0.14x | 0.14x | 0.28x | 0.05x | 0.27x | 0.49x | 0.64x | 0.92x |
| Asset Growth % | -0.09% | -0.28% | 0.98% | -0.18% | 0.19% | 0.91% | 0.76% | -0.06% | -0.06% | -0.05% |
| Total Current Liabilities | 64.45M | 54.36M | 74.84M | 69.48M | 92.33M | 105.65M | 103.72M | 105.51M | 149.99M | 160.38M |
| Accounts Payable | 9.31M | 4.27M | 6.34M | 7.77M | 13.99M | 18.71M | 27.81M | 14.36M | 20.89M | 11.64M |
| Days Payables Outstanding | 1.79K | 577.32 | 1.36K | 6.02K | 1.24K | 4.08K | 1.4K | 794.65 | 1.64K | 340.41 |
| Short-Term Debt | 27.8M | 28.24M | 35.15M | 33.7M | 38.58M | 30M | 0 | 0 | 0 | 35.45M |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 221K | 1000K | 150K | 1000K | 1000K | 0 | 0 |
| Other Current Liabilities | 22.56M | 19.4M | 21.89M | 23.08M | 6.19M | 44.58M | 52M | 36.46M | 86.59M | 64.66M |
| Current Ratio | 1.02x | 1.23x | 1.68x | 1.65x | 1.78x | 3.06x | 5.46x | 4.90x | 3.31x | 2.63x |
| Quick Ratio | 1.00x | 1.22x | 2.18x | 1.62x | 1.78x | 3.00x | 5.31x | 4.63x | 3.12x | 2.58x |
| Cash Conversion Cycle | -1.43K | -388.26 | - | -4.67K | - | -2.37K | -535.52 | 797.58 | 672.75 | -39.96 |
| Total Non-Current Liabilities | 12.38M | 33.91M | 19.66M | 28.13M | 44.7M | 248.32M | 591.42M | 739.08M | 822.5M | 805.97M |
| Long-Term Debt | 0 | 22.78M | 16.75M | 25.37M | 41.29M | 244.45M | 585.46M | 733.28M | 811.26M | 795.92M |
| Capital Lease Obligations | 2.38M | 2.7M | 2.75M | 2.7M | 3.41M | 3.87M | 5.96M | 5.8M | 11.23M | 10.05M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 329K | 244K | 155K | 54K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 76.83M | 88.27M | 94.49M | 97.61M | 137.03M | 353.98M | 695.14M | 844.6M | 972.49M | 966.35M |
| Total Debt | 32.38M | 53.72M | 54.72M | 61.82M | 84.65M | 279.5M | 593.24M | 741.45M | 825.15M | 841.42M |
| Net Debt | 3.48M | 31.62M | 4.44M | 35.09M | -29.52M | 7.38M | 88.85M | 436.69M | 714.5M | 736.5M |
| Debt / Equity | - | - | - | - | 2.21x | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -7.59x | -7.49x | -6.70x | -10.27x | -8.36x | -12.05x | -3.00x | -1.50x | -0.96x | -0.03x |
| Total Equity | -510.92M | -566.06M | -631.84M | -731.97M | 38.25M | -19.26M | -106.99M | -294.6M | -455.53M | -475.93M |
| Equity Growth % | -0.09% | -0.11% | -0.12% | -0.16% | 1.05% | -1.5% | -4.55% | -1.75% | -0.55% | -0.04% |
| Book Value per Share | -7.01 | -7.68 | -7.48 | -7.09 | 0.33 | -0.12 | -0.60 | -1.58 | -2.37 | -2.30 |
| Total Shareholders' Equity | -510.92M | -566.06M | -631.84M | -731.97M | 38.25M | -19.26M | -106.99M | -294.6M | -455.53M | -475.93M |
| Common Stock | 734K | 738K | 984K | 1.1M | 1.54M | 1.77M | 1.84M | 1.88M | 2.06M | 2.08M |
| Retained Earnings | -510.92M | -566.06M | -631.84M | -731.97M | -840.63M | -1.02B | -1.21B | -1.45B | -1.68B | -1.77B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -206K | -12K | -243K | -297K | 39K | 3K | 177K | 26K | 1.34M | 921K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -13.12M | -53.44M | -41.14M | -92.56M | -89.58M | -137.22M | -142.16M | -161.85M | -95.14M | -52.02M |
| Operating CF Margin % | -0.27% | -2.03% | -1.63% | -4.48% | -1.83% | -7.7% | -0.9% | -0.6% | -0.29% | -0.12% |
| Operating CF Growth % | 0.66% | -3.07% | 0.23% | -1.25% | 0.03% | -0.53% | -0.04% | -0.14% | 0.41% | 0.45% |
| Net Income | -43.02M | -55.14M | -65.78M | -101.25M | -108.9M | -182.81M | -184.06M | -247.12M | -226.54M | -88.88M |
| Depreciation & Amortization | 180K | 483K | 704K | 770K | 724K | 748K | 777K | 1.44M | 1.66M | 1.25M |
| Stock-Based Compensation | 9.71M | 8.49M | 12.62M | 9.4M | 0 | 0 | 34.64M | 44.7M | 55.62M | 65.41M |
| Deferred Taxes | 564K | -271K | 1.11M | 1.17M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 439K | 558K | 876K | 885K | 19.46M | 17.98M | -1.64M | 98.07M | 106.53M | 57.48M |
| Working Capital Changes | 19.02M | -7.55M | 9.33M | -3.53M | -872K | 26.88M | 8.12M | -58.95M | -32.4M | -87.28M |
| Change in Receivables | -7.38M | -2.52M | 2.65M | 568K | -17.85M | 13.9M | -20.82M | -21.47M | -6.09M | -22.7M |
| Change in Inventory | -929K | 1.11M | 500K | -1.65M | 1.65M | -7.04M | -8.77M | -12.42M | -1.45M | -4.16M |
| Change in Payables | 6.82M | -10.52M | 3.84M | 4.49M | 11.74M | 17.36M | 39.41M | -22.36M | -16.81M | -62.38M |
| Cash from Investing | -18M | 23.34M | -66.38M | 4.77M | 77.93M | -6.86M | 15.8M | -128.24M | -131.5M | 52.59M |
| Capital Expenditures | -5.12M | -5.28M | -328K | -366K | -343K | -514K | -2.38M | -1.35M | -2.17M | -1.12M |
| CapEx % of Revenue | 0.11% | 0.2% | 0.01% | 0.02% | 0.01% | 0.03% | 0.02% | 0% | 0.01% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.46M | 66K | -1.74M | -366K | 0 | 1K | 0 | 0 | 0 | 0 |
| Cash from Financing | 5.48M | 23.3M | 135.7M | 62.5M | 99.1M | 302.7M | 359.67M | 88.03M | 32.48M | -5.76M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 5.48M | 317K | 1.58M | 2.85M | 0 | 124.71M | 15.73M | 14.77M | -26.24M | -4.09M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -18.24M | -58.72M | -41.47M | -92.93M | -89.93M | -137.73M | -144.54M | -163.2M | -97.31M | -53.14M |
| FCF Margin % | -0.38% | -2.23% | -1.65% | -4.5% | -1.84% | -7.73% | -0.92% | -0.6% | -0.29% | -0.12% |
| FCF Growth % | 0.53% | -2.22% | 0.29% | -1.24% | 0.03% | -0.53% | -0.05% | -0.13% | 0.4% | 0.45% |
| FCF per Share | -0.25 | -0.80 | -0.49 | -0.90 | -0.78 | -0.82 | -0.81 | -0.88 | -0.51 | -0.26 |
| FCF Conversion (FCF/Net Income) | 0.30x | 0.97x | 0.63x | 0.91x | 0.82x | 0.75x | 0.77x | 0.65x | 0.42x | 0.59x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 900K | 0 | 22.14M | 30.38M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 118K | 3.54M | 1.43M | 1.6M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | - | -284.68% | -1925.37% | - | - | - | - |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | -179.63% | -38.79% | -0.73% |
| Gross Margin | 96.07% | 89.76% | 93.24% | 97.72% | 91.6% | 90.59% | 95.38% | 97.57% | 98.59% | 97.23% |
| Net Margin | -89.15% | -209.25% | -261.18% | -490.25% | -222.99% | -1026.35% | -117.11% | -91.25% | -68.36% | -19.72% |
| Debt / Equity | - | - | - | - | 2.21x | - | - | - | - | - |
| Interest Coverage | -7.59x | -7.49x | -6.70x | -10.27x | -8.36x | -12.05x | -3.00x | -1.50x | -0.96x | -0.03x |
| FCF Conversion | 0.30x | 0.97x | 0.63x | 0.91x | 0.82x | 0.75x | 0.77x | 0.65x | 0.42x | 0.59x |
| Revenue Growth | 254.62% | -45.39% | -4.43% | -18% | 136.45% | -63.53% | 782.38% | 72.31% | 22.37% | 36% |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Product | - | - | 17.53M | - | - | 267.71M | 324.7M | 442.67M |
| Product Growth | - | - | - | - | - | - | 21.29% | 36.33% |
| Collaborative And Other Research And Development | - | - | - | - | - | 214K | 6.72M | 8.04M |
| Collaborative And Other Research And Development Growth | - | - | - | - | - | - | 3038.32% | 19.77% |
| Milestone | - | - | - | - | - | - | - | - |
| Milestone Growth | - | - | - | - | - | - | - | - |
| Collaborative and Other Research and Development | - | 2.55M | 25M | - | 5.92M | - | - | - |
| Collaborative and Other Research and Development Growth | - | - | 879.58% | - | - | - | - | - |
| Service | - | - | - | 757K | - | - | - | - |
| Service Growth | - | - | - | - | - | - | - | - |
| Royalty | - | 6.1M | 6.3M | - | - | - | - | - |
| Royalty Growth | - | - | 3.31% | - | - | - | - | - |
| Supplemental NDA for RAPIVAB | 5M | - | - | - | - | - | - | - |
| Supplemental NDA for RAPIVAB Growth | - | - | - | - | - | - | - | - |
| RAPIVAB | 2M | - | - | - | - | - | - | - |
| RAPIVAB Growth | - | - | - | - | - | - | - | - |
BioCryst Pharmaceuticals, Inc. (BCRX) reported $599.8M in revenue for fiscal year 2024. This represents a 2954% increase from $19.6M in 2011.
BioCryst Pharmaceuticals, Inc. (BCRX) grew revenue by 36.0% over the past year. This is strong growth.
BioCryst Pharmaceuticals, Inc. (BCRX) reported a net loss of $8.8M for fiscal year 2024.
BioCryst Pharmaceuticals, Inc. (BCRX) generated $47.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.